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DObjective: The study objective was to determine whether recurrent or residual mild aortic regurgitation, which
occurs after valve-sparing aortic root replacement, progresses over time.
Methods: Between 2003 and 2008, 154 patients underwent Tirone David-V valve-sparing aortic root
replacement; 96 patients (62%) had both 1-year (median, 12  4 months) and mid-term (62  22 months)
transthoracic echocardiograms available for analysis. Age of patients averaged 38  13 years, 71% were
male, 31% had a bicuspid aortic valve, 41% had Marfan syndrome, and 51% underwent aortic valve repair,
predominantly cusp free margin shortening.
Results: Forty-one patients (43%) had mild aortic regurgitation on 1-year echocardiogram. In 85% of patients
(n¼ 35),mild aortic regurgitation remained stable on themost recent echocardiogram (median, 57 20months);
progression to moderate aortic regurgitation occurred in 5 patients (12%) at a median of 28  18 months and
remained stable thereafter; severe aortic regurgitation developed in 1 patient, eventually requiring reoperation.
Five patients (5%) hadmoderate aortic regurgitation at 1 year, which did not progress subsequently. Two patients
(2%) had more than moderate aortic regurgitation at 1 year, and both ultimately required reoperation.
Conclusions: Although mild aortic regurgitation occurs frequently after valve-sparing aortic root replacement,
it is unlikely to progress over the next 5 years and should not be interpreted as failure of the valve-preservation
concept. Further, we suggest that mild aortic regurgitation should not be considered nonstructural valve
dysfunction, as the 2008 valve reporting guidelines would indicate. We need 10- to 15-year follow-up to
learn the long-term clinical consequences of mild aortic regurgitation early after valve-sparing aortic root
replacement. (J Thorac Cardiovasc Surg 2014;147:169-78)Supplemental material is available online.
In patients with aortic root pathology and good aortic valve
cusp integrity, valve-sparing aortic root replacement
(V-SARR) offers an attractive alternative to a conventional
composite valve graft (CVG) with a mechanical or
bioprosthetic valve. Valve-sparing procedures alleviate the
need for anticoagulation with mechanical valves and
minimize the risk of early structural valve deterioration in
young patients receiving bioprosthetic valves. Although
these factors make V-SARR appealing, a key question ine Department of Cardiovascular and Thoracic Surgery,a and Division of
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The Journal of Thoracic and Cadeciding the best operative strategy is the expected
durability of the repair and identifying which patients are
at higher risk for failure. One of the risk factors predictive
of V-SARR failure is postoperative aortic regurgitation
(AR), which can progress and require reoperation.1-4
Previous reports have focused on postoperative AR and
reoperation; however, whether mild AR early after
V-SARR progresses has not been completely assessed. In
an elegant study from Hans Sievers’ group in L€ubeck,
Germany, by Hanke and colleagues,1 progression of AR
was analyzed after 2 types of V-SARR: Yacoub remodeling
(n¼ 108) and Tirone David reimplantation (n¼ 83). After a
median follow-up of 2.3 years, factors associated with
progression of AR included Marfan syndrome (MFS),
aortic valve repair (central plication with pericardial
pledgets), and preoperative annular diameter.1 The present
study sought to expand on those results over a longer
period of time in patients who underwent a Tirone
David-V Stanford modification V-SARR procedure.
MATERIALS AND METHODS
Study Cohort
From 2003 to 2008, 154 patients underwent Tirone David-V Stanford
modification V-SARR; 96 patients (62%) had both a 1-year follow-up trans-
thoracic echocardiogram (TTE) (median, 12  4 months after V-SARR;
interquartile range [IQR], 9-14months) and a recent,mid-termTTE (median,rdiovascular Surgery c Volume 147, Number 1 169
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AR ¼ aortic regurgitation
BAV ¼ bicuspid aortic valve
CTD ¼ connective tissue disorder
CVG ¼ composite valve graft
IQR ¼ interquartile range
MFS ¼ Marfan syndrome
TAV ¼ trileaflet aortic valve
TTE ¼ transthoracic echocardiogram
V-SARR ¼ valve-sparing aortic root replacement
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D62 22months after V-SARR; IQR, 44-82months) and constituted the study
cohort. For patientswithARprogression beyond 1 year, whichwas defined as
an increase in 1 or more AR grades, intervening TTEs were graded to
determine when the valve deteriorated. Clinical follow-up for all 96 patients
ranged from 1.8 to 9.2 years (mean, 5.3  1.8 years; median, 5.2  1.8;
IQR, 3.7-6.8 years), totaled 487 patient-years, and was 100% complete.
All TTE images were evaluated by a single American Society of
Echocardiography Level III trained echocardiographer (D. H. L.); degree
of AR was graded semiquantitatively on a scale from 0 to 4þ based on
jet width according to standard criteria.5 Quantitative methods, such as
quantitative Doppler and effective regurgitant orifice, could not be used
because of the disparate sources of echocardiography images and eccentric
AR jets. Where possible, AR grade of moderate or more was corroborated
by reversal of flow in the distal arch or descending aorta.
For comparison purposes, the total cohort was divided into 2 subgroups:
those with and those without mild AR on the 1-year TTE. Subset analysis
was then performed on the patients with early mild AR that subsequently
worsened. Because of early failure associated with the use of neo-suspensory
chords in patients with a bicuspid aortic valve (BAV),6,7 an additional set of
analyses was performed excluding the 2 patients with neo-suspensory chords.
Operative Procedure
The Stanford modification of the Tirone David-V V-SARR procedure
has been described.8 Depending on the extent of the aneurysm, total or
partial arch replacement using the ‘‘Peninsula technique’’ in patients
with a BAV was performed as described previously.9
Statistical Analysis
The preoperative and intraoperative characteristics listed in Tables 1 and
2 were compared between groups using chi-square tests for nominal and
ordinal variables, and general linear model multivariate analysis for scalar
variables. Factors found to have a P value less than .25 on multivariate
analysis for predicting AR progression were assessed using log-rank
(Mantel–Cox) analysis and nonparametric Kaplan–Meier actuarial curves.
Cox proportional-hazard regression analysis was attempted, but the model
was unstable because of an inadequate number of adverse events. All
statistical testing was performed using commercially available software
(SPSS Statistics 21; SPSS, IBM, New York, NY). Data are reported as
median or mean 1 standard deviation; IQR are included when
appropriate. The Stanford institutional review board approved the study,
and informed consent was obtained from the patients at time of contact.RESULTS
Preoperative and Intraoperative Characteristics
The average age of the total cohort (n¼ 96) was 38 13
years (IQR, 27-48 years), 71%were male, 31% had a BAV,170 The Journal of Thoracic and Cardiovascular Surgand 41% had MFS. Patients with a BAV were further
subdivided using the classification system by Sievers and
Schmidtke,10 with the majority being Sievers’ 1/L-R10
(Table 1).
There were no statistically significant differences
between the subgroups with or without early mild AR in
terms of age, incidence of connective tissue disorder
(CTD), incidence of BAV, or preoperative AR grade. There
were significantly more male patients in the subgroup
without early mild AR compared with the subgroup
with early mild AR (P ¼ .012), and this subgroup was
correspondingly taller (P ¼ .044). Arch replacement was
performed in 30 patients (31%, Table 2), and aortic valve
repair was performed in 49 patients (51%, free margin
shortening in all except 2 patients, raphe resection in
5 patients with BAV, and neo-suspensory chord creation in
2 patients with BAV). Preoperative and postoperative
annular diameters, as well as magnitude of annular
diameter change, were not significantly different between
the subgroups, nor was the need for concomitant aortic valve
repair. Mild AR on predischarge TTEwas evident in 17% of
patients in the subgroup withmildAR on 1-year TTE, which
was significantly higher than in the subgroup with no AR on
1-year TTE (0%, P ¼ .003). Timing of the 1-year TTE was
not different between subgroups; however, the time interval
between V-SARR and the most recent mid-term TTE was
significantly longer in the subgroup without early mild AR
(74  21 months vs 53  20 months, P ¼ .008, Table 3).
Incidence and Progression of Postoperative Aortic
Regurgitation
Forty-one patients (43%, Figure 1) had mild AR on the
1-year TTE; of this subgroup, 35 patients (85%) continued
to have mild AR on most recent TTE (median, 57  20
months; IQR, 40-73 months) and were included in
the ‘‘mild stable AR’’ subset. The mild AR in 5
patients (12%) progressed to moderate AR at a median of
28  18 months (IQR, 27-38 months), which remained
stable thereafter (median follow-up, 44  27 months;
IQR, 38-49 months). These 5 patients plus 1 patient with
AR that progressed to severe AR requiring reoperation
were included in the ‘‘progression of mild AR’’ subset
for comparison purposes. Among the patients in the
‘‘progression of mild AR’’ subset, AR grade increased
at a median of 28  17 months (IQR, 22-36 months)
postoperatively. Of note, only 1 patient (2%) with mild
AR on 1-year TTE had progression to greater than moderate
AR over the 53-month follow-up period.
Five patients (5%) had moderate AR on the 1-year TTE,
but the degree ofARdid not progress subsequently over ame-
dian follow-up of 49 28months (IQR, 46-95months). Four
of these patients initially had mild AR, and 1 patient had no
AR on the predischarge TTE. Two patients (2%) had more
than moderate AR on the 1-year TTE (both ultimatelyery c January 2014
TABLE 1. Preoperative patient characteristics
Total cohort (96 patients) No early AR (47, 49%) Mild early AR (41, 43%) P value
Age (y) 38  13 (27-48) 36  12 (27-45) 40  13 (29-50) .155
Gender, male 68 (71%) 38 (81%) 23 (56%) .012
Weight (lb) 179  41 (158-199) 186  43 (165-203) 175  35 (157-197) .189
Height (in) 72  5 (69-75) 73  4 (69-75) 71  4 (69-74) .044
BMI (kg/m2) 24  5 (21-28) 25  6 (21-28) 24  4 (22-27) .759
BSA (m2) 2.0  0.3 (1.9-2.2) 2.1  0.2 (2.0-2.2) 2.0  0.2 (1.9-2.2) .086
BAV (Sievers’ type): 30 (31%) 11 (23%) 14 (34%) .265
0-AP 4 (4%) 2 (4%) 2 (5%)
0-LAT 3 (3%) 1 (2%) 2 (5%)
1-L-R 21 (22%) 8 (17%) 9 (22%)
1-N-L 1 (1%) 0 (0%) 1 (2%)
1-R-N 1 (1%) 0 (0%) 0 (0%)
CTD: 41 (43%) 23 (49%) 16 (39%) .350
MFS 39 (41%) 22 (47%) 15 (37%)
Loeys–Dietz syndrome 2 (2%) 1 (2%) 1 (2%)
Preoperative AR: .521
None/trivial 36 (38%) 22 (47%) 14 (34%)
Mild (1þ) 28 (29%) 14 (30%) 12 (29%)
Moderate (2þ) 18 (19%) 8 (17%) 10 (24%)
Moderate-severe (3þ) 0 (0%) 0 (0%) 0 (0%)
Severe (4þ) 14 (15%) 3 (6%) 5 (12%)
LVEF (%) 61  6 (58-65) 60  7 (55-65) 62  4 (60-65) .096
Aortic dissection 1 (1%) 1 (2%) 0 (0%) .348
Previous cardiac surgery 2* (2%) 2* (4%) 0 (0%) .182
Data are presented as mean 1 standard deviationwith IQR in parentheses. For parametric variables, the total number of patients with the given characteristic is given followed by
the percentage of the group in parentheses. The first column lists data for the total study cohort (all 96 patients); data for the ‘‘no early AR’’ and ‘‘mild early AR’’ groups are listed
in the following 2 columns. For each group, the number of patients and percentage of the total study cohort (96 patients) are indicated in parentheses. P values listed are for the
comparisons between the ‘‘no early AR’’ and ‘‘mild early AR’’ groups. BAVs were classified using the classification system by Sievers and Schmidtke,10 where O indicates no
raphe and includes the subtypes of 0-AP and 0-LAT, and 1 indicates 1 raphe and includes the subtypes of 1-L-R, 1-N-L, and 1-R-N. AP, Anterior-posterior; AR, aortic
regurgitation; BAV, bicuspid aortic valve; BMI, body mass index; BSA, body surface area; CTD, connective tissue disorder; LAT, lateral; LVEF, left ventricular ejection fraction;
MFS,Marfan syndrome; 1-N-L, noncoronary cusp and left coronary cusp fusion; 1-L-R, left-right coronary cusp fusion; 1-R-N, right coronary cusp and noncoronary cusp fusion.
*Both patients had previous coarctation repairs.
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TTE. No patient had 4þ AR on the 1-year TTE.
Predictors of Progression of Mild Early Aortic
Regurgitation
Multivariate analysis identified aortic valve repair
(P ¼ .007), preoperative AR grade (P ¼ .014), and
specifically preoperative 4þ AR (P ¼ .002) to be related
to progression of early mild AR. Variables with a P value
less than .5 in the multivariate analysis (arch repair,
innominate cannulation, preoperative annular diameter,
CTD, gender, aortic valve repair, preoperative severe AR,
and preoperative AR grade) were entered into the actuarial
log-rank analysis. Aortic valve repair, preoperative AR
grade, and 4þ preoperative AR correlated significantly
with progression of mild AR (aortic valve repair:
P ¼ .006, preoperative AR grade: P ¼ .003, severe
preoperative AR: P < .001) (Figure E1). Predischarge
AR was not a significant predictor of AR progression on
multivariate analysis (P ¼ .252) or log-rank analysis
(P ¼ .919). Aortic valve repair and preoperative AR wereThe Journal of Thoracic and Caentered into a Cox proportional-hazards analysis, but the
model was found to be unstable. On the basis of our
previous experience that neo-suspensory commissural
chord creation in patients with a BAV who had ruptured
their ‘‘truncal valve-like’’ commissural suspensory chords
causing severe cusp prolapse failed early on,6,7 the
analysis was repeated excluding the 2 patients with BAV
with neo-suspensory chords. This revealed that preoperative
4þ AR and preoperative AR grade were no longer
associated with mild AR progression in the multivariate
(P ¼ .170 and P ¼ .313, respectively) or log-rank
(P ¼ .179 and .358, respectively) analyses, but aortic valve
repair remained significant (P ¼ .023 on multivariate
analysis, .019 on log-rank analysis).
Reoperation
A total of 4 patients (4%) required reoperation over a
median of 62  22 months of follow-up (Table 4): Two
patients with greater than moderate AR on the 1-year
TTE had progression to 3þ or 4þ AR 11 months after
V-SARR, 1 patient with mild AR on the 1-year TTE hadrdiovascular Surgery c Volume 147, Number 1 171
TABLE 2. Intraoperative data
Total cohort (96 patients) No early AR (47, 49%) Mild early AR (41, 43%) P value
Prerepair aortic valve annular diameter (cm) 28  3 (26-29) 28  3 (27-29) 27  3 (25-29) .890
Postrepair aortic valve annular diameter (cm) 24  3 (21-27) 25  3 (23-27) 23  3 (21-25) .615
Change in aortic valve annular diameter (cm) 4  4 (0-7) 3  4 (0-6) 4  4 (0-7) .837
CPB time (min) 297  74 (250-319) 291  75 (245-305) 304  77 (258-320) .263
Aortic crossclamp time (min) 232  55 (203-258) 231  54 (197-259) 235  45 (208-255) .252
SACP time (min) 29  10 (23-32) 31  13 (22-34) 27  5 (24-30) .395
Axillary/innominate cannulation 29 (30%) 13 (28%) 13 (32%) .678
Kay–Zubiate 1 (1%) 1 (2%) 0 (0%) .348
Arch replacement 30 (31%) 14 (30%) 12 (29%) .958
Concomitant procedures: .307
Mitral valve repair 7 (7%) 3 (6%) 3 (7%)
PFO closure 15 (16%) 8 (17%) 6 (15%)
Other 6 (6%) 2* (4%) 4y (10%)
Aortic valve repair: 49 (51%) 22 (47%) 20 (49%) .701
Free margin shortening 47 (49%) 21 (45%) 19 (46%)
Neo-suspensory chord 2 (2%) 0 (0%) 2 (5%)
Commissuroplasty 1 (1%) 1 (2%) 0 (0%)
Raphe resection 5 (5%) 2 (4%) 1 (2%)
Mild AR on predischarge TTE 14 (15%)z 0 (0%) 7 (17%) .003
Data are presented as mean 1 standard deviationwith IQR in parentheses. For parametric variables, the total number of patients with the given characteristic is given followed by
the percentage of the group in parentheses. The first column lists data for the total study cohort (all 96 patients); data for the ‘‘no early AR’’ and ‘‘mild early AR’’ groups are listed
in the following 2 columns. For each group, the number of patients and percentage of the total study cohort (96 patients) are indicated in parentheses. P values listed are for the
comparisons between the ‘‘no early AR’’ and ‘‘mild early AR’’ groups. Kay–Zubiate is a short interposition saphenous vein graft to coronary ostia. AR, Aortic regurgitation;
CPB, cardiopulmonary bypass; PFO, patent foramen ovale; SACP, selective antegrade cerebral perfusion; TTE, transthoracic echocardiogram. *Intra-aortic balloon pump
and ventricular assist device in 1 patient and ventricular assist device in 1 patient. yIntra-aortic balloon pump, ventricular assist device, and saphenous vein graft to left anterior
descending artery in 1 patient; saphenous vein graft to obtuse marginal in 1 patient; and repair of an anomalous left main with superficial femoral artery autograft in 1 patient;
repair of anomalous coronary artery fistula in 1 patient. zOne patient did not have a predischarge TTE.
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patient who had no AR on a TTE 7 months postoperatively
thereafter developed fulminant prosthetic endocarditis and
presented with 4þAR 1 month later, requiring replacement
with a homograft aortic root.
DISCUSSION
Incidence of Mild Aortic Regurgitation and
Progression
Mild AR was present on the 1-year TTE in 41 patients
(43%), but in the majority of these patients (85%) the
mild AR remained stable thereafter to a median follow-up
of 57  20 months. Although longer follow-up is clearly
needed, these results suggest that mild AR early after
V-SARR occurs in a considerable fraction of patients but
is unlikely to progress over the mid-term. In fact, only 1
patient (2%) progressed to greater than moderate AR.
Although these results are not directly comparable to the
elegant statistical modeling analysis from L€ubeck by HankeTABLE 3. Timing of postoperative transthoracic echocardiogram
Total cohort (96 patients) N
Timing of 1-y TTE (mo) 12  4 (9-14)
Timing of most recent TTE (mo) 62  22 (45-82)
Data are presented as median months 1 standard deviation after V-SARR. The first colum
‘‘mild early AR’’ groups are listed in the following 2 columns. For each group, the numb
parentheses. P values listed are for the comparisons between the ‘‘no early AR’’ and ‘‘mi
172 The Journal of Thoracic and Cardiovascular Surgand colleagues1 because of differences in patient substrate,
surgical technique (Tirone David-I or Yacoub vs Tirone
David-V with Stanford modification), and length of
follow-up, the findings in the analysis by Hanke and
colleagues1 are relevant. In the reimplantation group in
the series by Hanke and colleagues,1 there were many
patients with acute type A aortic dissection (42%) but
none in our study; there also were fewer patients with a
BAV (11% vs 31%) or MFS (20% vs 41%) in the series
by Hanke and colleagues.1 The patients in the L€ubeck
series also were more likely to have moderate or greater
preoperative AR (59% vs 34%), and fewer underwent
aortic valve repair (19% vs 51%).1 In terms of incidence
of AR after V-SARR, the mean predischarge AR grade in
the reimplantation group in the report by Hanke and
colleagues1 was 0.336  0.048 (mean  standard error);
although the number of patients with early mild AR was
not reported explicitly, on the basis of the standard error,
there were very few patients with mild AR on discharge,o early AR (47, 49%) Early mild AR (41, 43%) P value
12  4 (8-14) 12  4 (9-14) .951
74  21 (49-87) 53  20 (39-74) .008
n lists timing for the total study cohort (all 96 patients); data for the ‘‘no early AR’’ and
er of patients and percentage of the total study cohort (96 patients) are indicated in
ld early AR’’ groups. AR, Aortic regurgitation; TTE, transthoracic echocardiogram.
ery c January 2014
FIGURE 1. AR grade on preoperative and postoperative (1 year and most recent) TTE for all patients in the ‘‘mild early AR’’ subgroup (n¼ 41). Daughter
graphs demonstrate the corresponding data for ‘‘mild stable AR’’ (n ¼ 35) and ‘‘progression of mild AR’’ (n ¼ 6) subsets. AR, Aortic regurgitation;
TTE, transthoracic echocardiogram.
Stephens et al Acquired Cardiovascular Disease
A
C
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our study. Over the follow-up period (mean 3.09  2.92
years) in the L€ubeck series,1 mild AR developed in 25%
of the reimplantation group, considerably less than found
in the present study. By using linear fits for their data
using an average of 3 time points and then assuming a
linear increase in AR over the ensuing years, the authors
postulated the average AR grade at 10 years in theTABLE 4. Patients requiring reoperation
Patient
Preoperative
AR
Age,
gender BAV, CTD Notes on
Patient 1 4 11, M MFS MV repair (ring
double Alfier
(FM shorteni
Patient 2 4 18, M MFS
Patient 3 4 27, M BAV (Sievers and
Schmidtke 1-L-R)
AV repair (sutur
within L cusp
neo-suspenso
Patient 4 4 44, M BAV (Sievers and
Schmidtke 1-L-R)
AV repair (free
shortening), a
AR, Aortic regurgitation; AV, aortic valve; BAV, bicuspid aortic valve; CTD, connectiv
echocardiogram; 1-L-R, left-right coronary cusp fusion; FM, free margin. *Double Alfie
with fulminant prosthetic endocarditis and 4þ AR 8 months after V-SARR. Imaging show
sinuses and destruction of the valve cusps.
The Journal of Thoracic and Careimplantation group would be approximately 0.75.1
This linear extrapolation has not been validated; further,
our observations suggest that AR after V-SARR does not
progress linearly because the majority of our patients who
had mild AR at 1 year remained stable over a median
follow-up of 57  20 months. Additional long-term
follow-up is needed to answer the question about 10-year
and beyond durability.procedure
Pre– and post–aortic
valve annular
diameter (cm)
AR on
1-y TTE
Time to 3þ/4þ
AR (mo)
annuloplasty,
i*), AV repair
ng)
31, 23 4 11
47, 25 3 11
e closure of raphe
of fused L-R,
ry chord)
31, 27 1 20
margin
rch
26, 27 0 8y
e tissue disorder; MFS, Marfan syndrome; MV, mitral valve; TTE, transthoracic
ri stitches were used to correct prolapsing mitral valve scallop. yPatient presented
ed dehiscence of the left ventricular outflow tract between the right and noncoronary
rdiovascular Surgery c Volume 147, Number 1 173
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DRole of Aortic Valve Repair
In patients with good cusp quality, minimal calcification
(especially important in patients with BAV), and adequate
cusp motility, we continue to perform aortic valve repair.
After the dilated annulus is downsized, cusp prolapse
frequently is induced; we usually correct this with cusp
free margin shortening using 6-0 or 5-0 polytetrafluoroethy-
lene (Gore-Tex;WLGore &Associates Inc, Flagstaff, Ariz)
sutures (7-0 or 8-0 for patients with Loeys–Dietz syndrome)
near the nodulus of Aranti in the central belly of the cusp.
Cusp repair was performed in 51% of patients in this report
(96% of repairs included cusp free margin shortening).
A key element of successful V-SARR is adequate cusp
coaptation. Both the degree of coaptation and the
height of coaptation within the graft2,11 are important
determinants of long-term repair durability. We aim for a
5- to 9-mm cusp coaptation height with the coaptation
zone high within the graft.
V-SARR was historically chosen only if there was no
severe AR, the annulus was not markedly dilated, the
valve was trileaflet, and the cusps were normal; however,
over the last decade, repair of abnormal cusps has been
pursued more aggressively in attempts to avoid prosthetic
valve replacement.2,6,12,13 Knowledge of the exact
mechanism(s) causing the AR as promulgated by EI
Khoury and colleagues12 guides precise lesion-specific
valve and cusp repair strategies, which will hopefully
improve outcomes. As Svensson and colleagues13
concluded, a pathology-specific approach to valve-sparing
operations using reimplantation, remodeling, and sinotubu-
lar junction reduction strategies predicated on the specific
pathology yields excellent results across a diverse patient
population. Employing aortic valve repair techniques in
the context of reimplantation, several authors have
concluded that concomitant aortic valve repair is not a
risk factor portending higher reoperation rates.6,14,15
However, other series have identified aortic valve repair
as a risk factor for reoperation, including Pacini and
colleagues16 and Hanke and colleagues1 (who used central
plication with pericardial pledgets for cusp repair). Oka and
colleagues3 reported that certain cusp repairs, including
commissure repair and repair of thin cusps, led toworse out-
comes, emphasizing the importance of understanding the
intricacies and limitations of cusp repair. On the basis of
currently available clinical data, it is difficult to identify a
priori in advance in which individuals one should not
attempt to preserve the valve; however, as promulgated by
David and colleagues,14 we advocate that valves should
be spared only if there is good cusp integrity. Continued
technical refinement of repair techniques is ongoing, and
more remains to be learned; for example, because of failure
within 2 years after polytetrafluoroethylene (Gore-Tex; WL
Gore & Associates Inc, Flagstaff, Ariz) suture replacement174 The Journal of Thoracic and Cardiovascular Surgof ruptured truncal ‘‘commissural suspensory chords’’ in a
patient with BAV, we have been hesitant to use this tech-
nique.6,7 Triangular raphe resection and cusp plication is
avoided if possible because these maneuvers limit cusp
mobility.7 Although aortic valve repair was associated
with progression of mild AR in the present study, in all
except 1 patient the AR progressed to only 2þ, which re-
mained stable over the next 5 to 6 years. It should be
noted that in the entire Stanford experience, valve
repair was not a predictor of reoperation or greater than
2þ AR.6 Longer-term follow-up beyond 10 years is
essential to learn which valves should be repaired andwhich
replaced.
Influence of Bicuspid Aortic Valve
Although V-SARR initially was applied only in patients
with a trileaflet aortic valve (TAV), over time more
valve-preserving procedures have been done in patients
with a BAV if they have minimal cusp calcification or
fibrosis.14 Recent reports demonstrate over the mid-term
(5 years) that there are no differences in mortality or
reoperation rates after V-SARR in patients with a BAV
compared with those with a TAV,6 despite many differences
in preoperative and operative characteristics.6 The
follow-up of patients with BAV after V-SARR is relatively
short, however, and it is not realistic to expect BAVs to
function satisfactorily as long as normal TAVs in the
20þ-year time frame because a BAV can inexorably
become fibrotic and calcified and eventually stenotic.
Hanke and colleagues1 did not identify BAVas a risk factor
for AR after V-SARR (only 11% of the patients in the
L€ubeck series had a BAV), but follow-up was short.
Seasoned judgment and ample experience are mandatory
to determine which BAV cusps are suitable for V-SARR;
at Stanford, BAV cusps with significant fibrosis or
calcification are replaced. At this time, the presence of a
BAV apparently cannot be linked to progression of mild
AR over the mid-term, which justifies continuing to
preserve good-quality BAVs in young patients.
Impact of Connective Tissue Disorder
Given the proven long-term durability of a CVG
incorporating a mechanical prosthesis along with minimal
morbidity and mortality in young patients with MFS or
other CTD17 and the unknown long-term durability of
V-SARR in these patients, surgeons initially were reluctant
to offer V-SARR to those with MFS or other CTD. Over the
last 2 decades, however, the use of V-SARR in patients with
CTD has increased considerably, in part because of patient
demand and their desire to avoid lifelong anticoagulation.
Data continue to accrue regarding the durability of
V-SARR in these patients, but the long-term results still
remain unknown; 10-year data from the Stanford overallery c January 2014
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between patients with and without CTD,6 consistent with
the results of Shrestha and colleagues.2 In fact, the most
recent analysis of David and colleagues’14 V-SARR series
(mean follow-up 6.9 years, 36% with MFS) found MFS
to be protective from death, probably because of the
younger age of the patients with MFS. However, it is
important to note that there were only 62 patients remaining
at risk at 10 years and 21 patients at 14 years. An analysis
from the Homburg group18 similarly suggested V-SARR
in patients with MFS might have superior event-free
survival compared with a CVG. In the report by Hanke
and colleagues,1 however, MFS was a risk factor for AR
progression using the remodeling or the reimplantation
techniques. The National Marfan Foundation Aortic Root
Registry Study (Aortic Valve Operative Outcomes in
Marfan Patients) enrolled 316 patients meeting rigorous
Ghent criteria for MFS from 19 centers (15 in North
America) and currently is assessing the outcomes of
V-SARR versus CVG out to 10 years to address this
unanswered question.19
Preoperative Annular Diameter and Degree of
Preoperative Aortic Regurgitation
Preoperative annular diameter and the magnitude of
annular reduction have been associated with recurrent AR
and reoperation in some reports,1,20,21 including our
recent analysis of V-SARR for BAV.7 In the present
2003-2008 cohort, in the analysis of the complete Stanford
V-SARR experience from 1993 to 2009,6 and the series by
Leyh and colleagues,22 however, no adverse impact was
apparent. In the study by Hanke and colleagues,1 smaller
preoperative diameter was a risk factor for AR in
the patients undergoing the David reimplantation, but
paradoxically a larger annulus was linked with more late
AR in the patients undergoing remodeling. The authors
postulated a smaller neo-annular area after reimplantation
may have increased turbulent flow and earlier cusp failure
leading to AR, but this is speculative.1
The association between preoperative grade of AR and
recurrent AR after V-SARR continues to be debated.
Consonant with the recent analysis of our 1993-2009
overall Tirone David V-SARR experience in which patients
with preoperative 4þ AR were at higher risk for structural
valve deterioration and reoperation,6 preoperative 4þ AR
also was a risk factor for progression of early mild AR in
the present study. When the 2 BAV patients with neo-
suspensory chords were excluded, however, preoperative
4þ AR no longer was a significant risk factor for progres-
sion of mild AR, and only 1 patient with progression of
early mild AR in this study required reoperation (he had a
BAV, 4þ preoperative AR, and neo-suspensory chord
repair). Further, our current analysis is limited by the few
number of patients with preoperative 4þ AR and largeThe Journal of Thoracic and Cavariability of the dependent end points. The Hannover
group found that preoperative AR was a risk factor for
30-day mortality, but not for reoperation.2 Leshnower and
colleagues23 concluded that 3þ or greater preoperative
AR was not associated with a higher risk of moderate AR
postoperatively over the short-term (mean follow-up of 19
months), similar to the findings of Hanke and colleagues1
(mean follow-up of 3 years). De Kerchove and colleagues15
reported that 3þ or greater preoperative AR did not increase
the likelihood of recurrent AR or need for reoperation
(mean follow-up of 5 years), echoing David and col-
leagues’14 recent findings analyzing David’s entire career
experience (mean follow-up of 7 years). Valves that are
leaking badly can be challenging to repair, and
certain repair strategies (eg, creation of commissural
neo-suspensory chords, Trussler stitches, and formal cusp
plication) may not prove durable. Longer follow-up in
larger numbers of patients is required to elucidate the
optimal management of patients with preoperative 4þ
AR. We have been increasingly selective in performing V-
SARR on patients with 4þ preoperative AR, but will do
so if the cusps are of good quality with minimal
calcification.
Mechanisms of Recurrent Aortic Regurgitation
Postoperatively
Investigation continues regarding the mechanisms res-
ponsible for AR after V-SARR. Certain causative factors
such as endocarditis and cusp repair failure are well
established, but fortunately these are rare. The mechanisms
underlying slowly progressive AR, however, are still being
elucidated. Creating inadequate coaptation height at opera-
tion is likely to lead to AR progression, and cusp coaptation
below the level of the annulus also has been implicated.14
Progressive cusp degeneration has been noted in a variety
of inflammatory or autoimmune diseases in patients after
V-SARR.3 Theoretically, abnormal perturbation of cusp
diastolic closing stresses and abnormal stress distribution
due to certain operative techniques, noncompliant fabric
grafts, elimination of normal aortic annular 3-dimensional
motion, or altered cusp geometry24 may contribute to valve
degeneration over time. Finally, in patients with BAV, the
intrinsic inflammatory and calcification processes may
progress despite correction of the valvular hemodynamic
abnormality, which can lead to valve failure over the
long-term.6,7 Progressive annular dilation reducing
the height of the cusp coaptation zone has been seen
after the Yacoub remodeling technique in patients with
MFS, which has prompted most surgeons to abandon the
remodeling technique. Paying particularly strict attention
to restoring normal valve annular and cusp geometry,
ensuring adequate cusp coaptation height high within
the graft, and being careful regarding repair of
thin cusps should minimize late progressive AR afterrdiovascular Surgery c Volume 147, Number 1 175
Acquired Cardiovascular Disease Stephens et al
A
C
DV-SARR, but further research clarifying the specific
mechanisms underlying deterioration of these valves is
needed.
According to the 2008 version of the American
Association for Thoracic Surgery/Society of Thoracic
Surgeons/European Association for Cardio-Thoracic
Surgery valve-reporting guidelines,25 residual or recurrent
1þ AR is considered ‘‘nonstructural valve dysfunction.’’
Conversely, Akins and colleagues25 stipulated that 1þ or
mild mitral regurgitation after open surgical or catheter
interventional mitral repair was not nonstructural
valve dysfunction. On the basis of the benign prognosis of
mild AR after V-SARR observed in this analysis, we
suggest that the next iteration of the valve-reporting
guidelines be modified to include only 2þ or greater
AR after aortic valve repair or V-SARR as nonstructural
valve dysfunction.
Study Limitations
This is a single institution analysis examining only a
5-year interval selected to provide mid-term follow-up.
The beginning of the sample window (2003) was chosen
on the basis of when we began using the ‘‘Tirone
David-V Stanford Modification V-SARR’’ procedure.
With the exception of the incidence of preoperative
aortic dissection and the use of Kay–Zubiate coronary
reconstruction (Tables E1 and E2), there were no
significant differences in preoperative and intraoperative
characteristics between the patients who had serial TTEs
available for analysis allowing for their inclusion in the
study and those who did not. Longer follow-up in larger
numbers of patients is obviously needed to determine the
long-term clinical consequences of early mild AR observed
at 1 year. With so few adverse events (progression of mild
AR), we were unable to perform a meaningful Cox
proportional-hazards analysis to calculate hazard ratios,
compare the relative predictive values of factors, or identify
interactions between variables.
CONCLUSIONS
Although mild AR frequently occurs early after
V-SARR, this mild AR remained stable over the next 5
years in the majority of patients. The need for aortic valve
repair and degree of preoperative AR were possibly
associated with progression of mild, early AR;
however, AR progression was almost exclusively from
mild to 2þ (moderate) AR. Longer follow-up is required
to determine the long-term clinical implications of this
mild AR early after V-SARR.
The authors thank Arlene Correa, PhD, for consultation
regarding statistical analysis; Sunny Pellone, Kathleen Gallagher,
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DDiscussion
Dr Leonard Girardi (New York, NY). The Stanford group once
again should be congratulated on their continued commitment to
the analysis and improvement of V-SARR. In the 154 patients
they included in this series, 62% had both 1- and 5-year follow-
up echocardiography imaging; 43% of these had aortic insuffi-
ciency (AI); 85%, as you said, never progressed any further than
mild AI. Of the 5 or 6 who did progress, once they get to 2+ or
moderate AI, again, a gratifying number, 80% went no further
and only 1 subsequently went on to require aortic valve
replacement.
In the patients who underwent reoperation, 4 of the 96, an
outstanding rate, 2 additional patients required surgery for valve
deterioration. One person developed endocarditis. So only 1 of
these patients went from mild AI at 1 year to surgery in the future.
The 2 patients who required surgery without endocarditis quickly
experienced significant AI.
The indications for this procedure have continuously expanded
over the years to an increasingly complex and diverse patient
population. No longer are we offering this operation just to young
patients with ascending aortic aneurysms, TAVs, and minimal AI.
This collection of patients certainly represents what I would
think is a ‘‘real world’’ look at aortic root replacement and aortic
valve-sparing surgery. It includes patients with bicuspid valves,
advanced CTDs, a few aortic dissections, and reoperations. Fifteen
percent of their patients had severe AI at the time of surgery.
Despite Dr Miller’s extensive experience with this surgery and
other root replacement, 43% had AI at the time of 1-year
follow-up; 17% had mild AI before they even left the hospital,
and this is in extremely experienced hands.
So, again, it is not surprising to me that these patients have AI.
These data reassure us that just because you have AI at 1 year,
even if it’s moderate, all is not lost. This should be reassuring to
not only the surgeons performing the surgery but also the cardiolo-
gists following them and, most important, the patient. As patients
get their echocardiography reports and hear that they have AI,
they can go into a tailspin by thinking a reoperation is right
around the corner. That clearly is not the case and to me the most
important result of this study. I have a number of questions for you.
On your more advanced multivariate analysis, the only risk
factor that really was significantly predictive of the need for
reoperation was aortic valve repair. I know at least for us at
Cornell, one of the problems we have is trying to figure out who
really needs valve repair and who doesn’t. I question sometimes
whether we do too many of them and whether we are actuallyThe Journal of Thoracic and Cadoing more harm than good. What techniques do you use at
Stanford to try to sort out who could benefit from a valve repair
and those we should leave alone? Do you have a way to know
who they are?
Dr Stephens. Thank you, Dr Girardi, for your excellent ques-
tions. Regarding aortic valve repair, we often don’t know whether
we are going to need to add any cusp repair until that graft is sutured
down and the final neo-annular geometry can be appreciated; then
we see if we have induced any new prolapse or there was prolapse
present before the graft that needs attention.We do not always know
ahead of time which patients are going to need aortic cusp repairs.
That said, yes, we continue to do valve-sparing procedures in
patients who need cusp repairs. I think it comes down to, as
Dr David continues to say, the quality of the cusps. If the cusps
are of good quality, and, in particular in the patients with bicuspid
valves, have minimal fibrosis or calcification, then we feel we can
achieve a durable repair and proceed. This is based on the
analysis of the entire Stanford experience that was presented at
the American Association for Thoracic Surgery last year in which
aortic valve repair was not a predictor of reoperation or recurrent
AR. So we have continued to do aortic valve repair, and, as you
saw, most frequently it is cusp free margin shortening. The analysis
of the entire Stanford experience is consistent with other large
series in which aortic valve repair was not a significant predictor
of AR recurrence or reoperation.
Dr Girardi. After you have reimplanted the valve and you look
down through and see obvious prolapse, you sort of know it when
you see it. But other than those patients, are you waiting until the
patient comes off bypass to figure out who needs valve repair? Did
you re-clamp and re-pledge, because a lot of these patients have
had long crossclamp times, long pump runs, and another period
of myocardial ischemia might not be the right thing. Your data
would suggest that coming off bypass with a little bit of AI, or
maybe even 1-1/2+ AI, is not such a bad thing. We could leave
them with that rather than taking the risk of another period of
ischemia. Is that how it is done?
Dr Stephens. To address your question of what our limit is in
terms of AR coming out of the operating room, we do not leave
with anything more than with anything more than trace (or mild
at the worst) AR; we always ‘‘stress test’’ the valve by increasing
the systolic blood pressures to at least 150 mm Hg to see whether
the valve leaks. Luckily, in the more than 300 cases that Dr Miller
has done since 1993, he has never had to re-crossclamp to re-repair
a valve or convert to valve replacement on the table.
Dr Girardi. So experience is more important than anything. Is
that what you are saying?
Dr Stephens. Absolutely.
Dr Girardi. Of the patients who did fail, 2 of them had a lot of
AI fairly early on, within 1 year, and if you look at the data, which
were not presented here because of time constraints, although
preoperative annular diameter was not found to be predictive of
failure, 2 of those patients had a big annulus. One was a 35- or
34-mm annulus in an 11-year-old, and another had an annulus
that was in excess of 40 mm. So it just may be that there is too
small of a number to predict valve failure.
If you had to do that again, would those patients still get a
valve-sparing root, or are there limits to what you will do? As
you said, a CVG after coming off bypass has not been necessary,rdiovascular Surgery c Volume 147, Number 1 177
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going to work?
Dr Stephens. Two points with regard to those excellent
questions, the first regarding reoperation. We had 4 reoperations;
1 case was the 11-year-old boy with MFS you mentioned with a
huge annulus, very poor tissue integrity, and who also needed a
very complicated mitral repair; Dr Miller in hindsight feels saving
these valves was a judgment error in this particular patient.
Another patient who required reoperation had a BAV and 4+ AR
preoperatively; gross prolapse of the fused left-right coronary
cusp was due to rupture of truncal-valve type of suspensory chor-
dae in the left-right commissure. He received commissural neo-
suspensory chords using polytetrafluoroethylene (Gore-Tex; WL
Gore & Associates Inc, Flagstaff, Ariz) suture that pulled out of
the tissue after 20 months, leading to acute recurrent 4+ AR. We
have been more hesitant in light of that particular patient to use
commissural neo-suspensory polytetrafluoroethylene (Gore-Tex)
chords. We learned hard lessons from both of these patients.
Dr Tirone David (Toronto, Ontario, Canada). I don’t know
howmany of you know, but Elizabeth Stephens is a surgical intern.
I have to commend her to be brave enough to stand in an audience
of mostly men and present us her study.
Elizabeth, aortic valve repair is nodifferent thanmitral valve repair
and likely the single most important thing, more important than how
little the valve is leaking in the operating room is morphology of the
cusps when you finish the reimplantation or remodeling. As in mitral
valve repair, we talk about leaflets coaptation area, and the coaptation
has to bewithin the ventricle. In the aortic valve, the coaptation has to
be within the aortic root. So if the cusps are coapting 4 to 6 mm, and
they are 8 mm inside the aortic root, and there is mild AI, reassure
yourself that things will alright for the next 20 years. We have done
that, and they seldom fail.
If at the end of the operation the cusps coapt at the level of the
annulus or below, it is usually bad news because they will come178 The Journal of Thoracic and Cardiovascular Surgback with AI. This has been our experience with tricuspid aortic
valves. I am a late comer in BAV reimplantation, but Dr Sch€afers
has more experience than anybody else, and he may say the same
for BAVs. Did you look at morphology of the cusps and try to
correlate it with AI?
Dr Stephens. We have not looked at morphology.
Dr David. But you have the data, don’t you; you have the
intraoperative echocardiograms?
Dr Stephens. Yes.
DrHans-Joachim Sch€afers (Homburg/Saar, Germany). I would
like to repeat the topic that Tirone has started, that is, valve
morphology. Multiple series have shown that if you achieve normal
valve morphology, the valve will be stable at the end of the opera-
tion. There are essentially 2 ways of assessing valve morphology:
One is eyeballing, and the other is actual measurement, such
as measurement of effective height. What was the primary
parameter? Was it eyeballing or some objective measurement, and
if so, what?
Dr Stephens. In general, we aim for a goal of 5 to 9 mm of
coaptation height (or ‘‘effective coaptation height’’ as you define
it, Dr Sch€afers); as Dr David alluded to, that coaptation zone has
to be relatively high within the graft, but we have not objectively
measured that variable. I don’t know if Dr Miller can comment
on that.
Dr Miller. Hans-Joachim, we eyeball it and do not have your
little J-shaped tool to directly measure ‘‘effective coaptation
length.’’ Maybe we should. We have tried to estimate coaptation
zone height from the postoperative TTEs, but that is probably
not terribly accurate. I agree that the geometric principles that Tir-
one David and you told us about are important.
Thank you, Tirone, for pointing out that Elizabeth Stephens is a
postgraduate year 1 (intern) at Columbia. If I were an intern
up here in front of this audience, I’d be in supraventricular
tachycardia with a heart rate over 200.ery c January 2014
FIGURE E1. A, Log-rank (Mantel–Cox) analysis of progression of AR in patients with mild AR on the 1-year TTE. Error bars indicate standard error of
the estimate. Number of patients at risk in each group is listed under the x-axis. Note the relatively few number of patients at risk (n¼ 14) at 60 months. On
log-rank analysis, aortic valve repair versus no repair has a P value of .006. All patients, except 1 with AR that progressed to moderate, remained stable at the
time of the latest follow-up echocardiogram. B, Log-rank (Mantel–Cox) analysis of progression of AR in patients with mild AR on the 1-year TTE.
Error bars indicate standard error of the estimate. Number of patients at risk in each group is listed under the x-axis. Note the relatively few number of
patients at risk (14) at 60 months. On log-rank analysis, preoperative AR grade had a P value of .003. All patients, except 1 with AR that progressed to
moderate, remained stable through the latest follow-up. The red labels on the severe preoperative AR curves indicate the most recent AR grade for the
patients in whom AR progressed. The patient with 4þ AR ultimately underwent reoperation. AR, Aortic regurgitation; AV, atrioventricular.
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TABLE E1. Preoperative patient characteristics (2003-2008)
Total cohort (154) AR study cohort (96, 62%)
Patients without 1-y
echocardiogram (58, 38%) P value
Age (y) 38  13 (27-49) 38  13 (27-48) 39  13 (26-49) .616
Gender, male 113 (73%) 68 (71%) 45 (78%) .358
Weight (lb) 181  37 (160-202) 179  41 (158-199) 185  29 (162-204) .343
Height (in) 72  5 (69-75) 72  5 (69-75) 72  4 (69-75) .491
BMI (kg/m2) 25  5 (22-28) 24  5 (21-28) 26  4 (23-28) .508
BSA (m2) 2.0  0.2 (1.9-2.2) 2.0  0.3 (1.9-2.2) 2.0  0.2 (1.9-2.2) .342
BAV (Sievers and Schmidtke type): 49 (32%) 30 (31%) 19 (33%) .846
0-AP 6 (4%) 4 (4%) 2 (3%)
0-LAT 9 (6%) 3 (3%) 6 (10%)
1-L-R 31 (20%) 21 (22%) 10 (17%)
1-N-L 1 (1%) 1 (1%) 0 (0%)
0-R-N 2 (1%) 1 (1%) 1 (2%)
CTD: 65 (42%) 41 (43%) 24 (41%) .504
MFS 60 (39%) 39 (41%) 21 (36%)
Loeys–Dietz syndrome 5 (3%) 2 (2%) 3 (5%)
Preoperative AR: .713
None/trivial 40 (26%) 29 (30%) 11 (19%)
Mild (1þ) 30 (19%) 17 (18%) 13 (22%)
Moderate (2þ) 15 (10%) 0 (0%) 15 (26%)
Moderate-Severe (3þ) 15 (10%) 0 (0%) 15 (26%)
Severe (4þ) 20 (13%) 14 (14%) 6 (10%)
LVEF (%) 61  6 (60-65) 61  6 (58-65) 61  6 (60-65) .425
Aortic dissection 6 (4%) 1 (1%) 5 (9%) .019
Previous cardiac surgery 6 (4%) 2 (2%) 4 (7%) .135
Data are presented as mean 1 standard deviationwith IQR in parentheses. For parametric variables, the total number of patients with the given characteristic is given followed by
the percentage of the group in parentheses. The first column lists data for all patients undergoing V-SARR at Stanford from 2003 to 2008, the second column lists data for the
subgroup of patients with 1-year follow-up echocardiograms included in the present study, and the third column lists data for the remaining patients for whom no 1-year follow-up
echocardiogram was available and who were excluded from the present study. P values listed are for the comparisons between the patients included in the present study and those
excluded. BAVs were classified using the system by Sievers and Schmidtke,10 where O indicates no raphe and includes the subtypes of 0-AP and 0-LAT, and 1 indicates 1 raphe
and includes the subtypes of 1-L-R, 1-N-L, and 1-R-N. AP,Anterior-posterior; AR, aortic regurgitation; BAV, bicuspid aortic valve;BMI, body mass index;BSA, body surface area;
CTD, connective tissue disorder; LAT, lateral; LVEF, left ventricular ejection fraction;MFS,Marfan syndrome; 1-N-L, noncoronary cusp and left coronary cusp fusion; 1-L-R, left-
right coronary cusp fusion; 1-R-N, right coronary cusp and noncoronary cusp fusion.
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TABLE E2. Intraoperative data: Total cohort 2003-2008
Total cohort (154) AR study cohort (96, 62%)
Patients without 1-y
echocardiogram (58, 38%) P value
Prerepair aortic valve annular
diameter (cm)
28  4 (26-29) 28  3 (26-29) 27  2 (25-29) .780
Postrepair aortic valve
annular diameter (cm)
22  2 (21-23) 24  3 (21-27) 22  2 (21-23) .754
Change in aortic valve annular
diameter (cm)
6  3 (4-8) 4  4 (0-7) 6  2 (4-8) .644
CPB time (min) 298  66 (255-323) 297  74 (250-319) 300  50 (259-325) .847
Aortic crossclamp time (min) 235  50 (204-260) 232  55 (203-258) 240  41 (203-262) .728
SACP time (min) 29  11 (23-32) 29  10 (23-32) 29  13 (23-29) .944
Axillary/innominate
cannulation
52 (34%) 29 (30%) 23 (40%) .230
Kay–Zubiate 5 (3%) 1 (1%) 4 (7%) .047
Arch replacement 53 (34%) 30 (31%) 23 (40%) .287
Concomitant procedures: .099
Mitral valve repair 10 (6%) 7 (7%) 3 (5%)
PFO closure 23 (15%) 17 (18%) 8 (14%)
Other 7 (3%) 6 (6%) 1 (2%)
Aortic valve repair: 81 (53%) 49 (51%) 32 (55%) .619
Free margin shortening 80 (52%) 48 (50%) 32 (55%)
Neo-suspensory chord 4 (3%) 3 (3%) 1 (2%)
Commissuroplasty 1 (1%) 1 (1%) 0 (0%)
Raphe resection 7 (5%) 5 (5%) 2 (3%)
Data are presented as mean 1 standard deviationwith IQR in parentheses. For parametric variables, the total number of patients with the given characteristic is given followed by
the percentage of the group in parentheses. The first column lists data for all patients undergoing V-SARR at Stanford from 2003 to 2008, the second column lists data for the
subgroup of patients with a 1-year follow-up echocardiogram and therefore were included in the present study, and the third column lists data for the remaining patients for whom
no 1-year follow-up echocardiogram was available and who were excluded from the present study. P values listed are for the comparisons between the patients included and
excluded in the present study. Kay–Zubiate is a short interposition saphenous vein graft to coronary ostia. AR, Aortic regurgitation; CPB, cardiopulmonary bypass; PFO, patent
foramen ovale repair; SACP, selective antegrade cerebral perfusion.
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